Sun Pharma Advanced [SPARC] vs Divi's Laboratories [DIVISLAB] Detailed Stock Comparison
Sun Pharma Advanced
NSE
Loading...
Divi's Laboratories
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Sun Pharma Advanced wins in 6 metrics, Divi's Laboratories wins in 12 metrics, with 0 ties. Divi's Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Sun Pharma Advanced | Divi's Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -13.68 | 69.93 | Sun Pharma Advanced |
| Price-to-Book Ratio | -21.57 | 10.80 | Sun Pharma Advanced |
| Debt-to-Equity Ratio | -1.24 | 0.03 | Sun Pharma Advanced |
| PEG Ratio | 0.30 | 2.64 | Sun Pharma Advanced |
| EV/EBITDA | -17.40 | 51.62 | Sun Pharma Advanced |
| Profit Margin (TTM) | -53.22% | 23.89% | Divi's Laboratories |
| Operating Margin (TTM) | -568.05% | 25.60% | Divi's Laboratories |
| EBITDA Margin (TTM) | N/A | 25.60% | N/A |
| Return on Equity | 157.88% | 14.64% | Sun Pharma Advanced |
| Return on Assets (TTM) | -102.08% | 12.94% | Divi's Laboratories |
| Free Cash Flow (TTM) | $-3.71B | $2.15B | Divi's Laboratories |
| Dividend Yield | N/A | 0.91% | N/A |
| 1-Year Return | -33.63% | 11.63% | Divi's Laboratories |
| Price-to-Sales Ratio (TTM) | 72.37 | 17.05 | Divi's Laboratories |
| Enterprise Value | $49.34B | $1,582.14B | Divi's Laboratories |
| EV/Revenue Ratio | 76.39 | 16.39 | Divi's Laboratories |
| Gross Profit Margin (TTM) | -10.68% | 60.33% | Divi's Laboratories |
| Revenue per Share (TTM) | $2 | $363 | Divi's Laboratories |
| Earnings per Share (Diluted) | $-9.19 | $87.12 | Divi's Laboratories |
| Beta (Stock Volatility) | 0.30 | 0.23 | Divi's Laboratories |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Sun Pharma Advanced vs Divi's Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Sun Pharma Advanced | -1.15% | -1.85% | -3.47% | -9.97% | -9.63% | -29.74% |
| Divi's Laboratories | -0.68% | 0.59% | -0.96% | -8.19% | 3.08% | 0.32% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Sun Pharma Advanced | -33.63% | -35.95% | -18.26% | -63.10% | 54.94% | -51.49% |
| Divi's Laboratories | 11.63% | 64.43% | 98.78% | 441.10% | 1,634.12% | 7,906.97% |
News Based Sentiment: Sun Pharma Advanced vs Divi's Laboratories
Sun Pharma Advanced
News based Sentiment: MIXED
September presented a mixed bag for SPARC, with disappointing financial results offset by a significant analyst upgrade and fluctuating share prices. While the company continues to struggle with revenue and profitability, the positive sentiment from analysts suggests potential for future turnaround, making it a noteworthy month for investors.
Divi's Laboratories
News based Sentiment: MIXED
September brought both challenges and opportunities for Divi's Laboratories. While sequential declines in financial results and a downgrade raised concerns, positive analyst coverage from JPMorgan and StockInvest.us, coupled with expansion into high-growth areas, offered a more optimistic outlook. This creates a mixed investment narrative.
Performance & Financial Health Analysis: Sun Pharma Advanced vs Divi's Laboratories
| Metric | SPARC | DIVISLAB |
|---|---|---|
| Market Information | ||
| Market Cap | ₹46.74B | ₹1.63T |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 205,981 | 416,899 |
| 90 Day Avg. Volume | 222,297 | 389,167 |
| Last Close | ₹139.39 | ₹6,051.00 |
| 52 Week Range | ₹109.30 - ₹241.00 | ₹4,955.00 - ₹7,071.50 |
| % from 52W High | -42.16% | -14.43% |
| All-Time High | ₹875.00 (Apr 24, 2006) | ₹7,071.50 (Jul 08, 2025) |
| % from All-Time High | -84.07% | -14.43% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.43% | 0.14% |
| Quarterly Earnings Growth | -0.43% | 0.27% |
| Financial Health | ||
| Profit Margin (TTM) | -0.53% | 0.24% |
| Operating Margin (TTM) | -5.68% | 0.26% |
| Return on Equity (TTM) | 1.58% | 0.15% |
| Debt to Equity (MRQ) | -1.24 | 0.03 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹-6.69 | ₹563.87 |
| Cash per Share (MRQ) | ₹0.06 | ₹132.86 |
| Operating Cash Flow (TTM) | ₹-3,484,287,000 | ₹19.67B |
| Levered Free Cash Flow (TTM) | ₹-3,425,094,000 | ₹21.91B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.91% |
| Last 12-Month Dividend | N/A | ₹60.00 |
Valuation & Enterprise Metrics Analysis: Sun Pharma Advanced vs Divi's Laboratories
| Metric | SPARC | DIVISLAB |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -13.68 | 69.93 |
| Forward P/E | 2.60 | 108.21 |
| PEG Ratio | 0.30 | 2.64 |
| Price to Sales (TTM) | 72.37 | 17.05 |
| Price to Book (MRQ) | -21.57 | 10.80 |
| Market Capitalization | ||
| Market Capitalization | ₹46.74B | ₹1.63T |
| Enterprise Value | ₹49.34B | ₹1.58T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 76.39 | 16.39 |
| Enterprise to EBITDA | -17.40 | 51.62 |
| Risk & Other Metrics | ||
| Beta | 0.30 | 0.23 |
| Book Value per Share (MRQ) | ₹-6.69 | ₹563.87 |
Financial Statements Comparison: Sun Pharma Advanced vs Divi's Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SPARC | DIVISLAB |
|---|---|---|
| Revenue/Sales | ₹96.40M | ₹24.10B |
| Cost of Goods Sold | ₹106.70M | ₹9.56B |
| Gross Profit | ₹-10.30M | ₹14.54B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-547.60M | ₹6.17B |
| EBITDA | ₹-429.40M | ₹8.48B |
| Pre-Tax Income | ₹-518.10M | ₹7.33B |
| Income Tax | ₹600,000 | ₹1.88B |
| Net Income (Profit) | ₹-518.70M | ₹5.45B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SPARC | DIVISLAB |
|---|---|---|
| Cash & Equivalents | ₹19.64M | ₹4.15B |
| Total Current Assets | ₹261.97M | ₹100.81B |
| Total Current Liabilities | ₹3.74B | ₹14.52B |
| Long-Term Debt | ₹1.07B | ₹20.00M |
| Total Shareholders Equity | ₹-2.17B | ₹149.69B |
| Retained Earnings | ₹-23.22B | ₹134.00B |
| Property, Plant & Equipment | ₹178.02M | ₹3.19B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SPARC | DIVISLAB |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SPARC | DIVISLAB |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 205,981 | 416,899 |
| Average Daily Volume (90 Day) | 222,297 | 389,167 |
| Shares Outstanding | 324.52M | 265.47M |
| Float Shares | 91.74M | 120.77M |
| % Held by Insiders | 0.73% | 0.52% |
| % Held by Institutions | 0.02% | 0.29% |
Dividend Analysis & Yield Comparison: Sun Pharma Advanced vs Divi's Laboratories
| Metric | SPARC | DIVISLAB |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹60.00 |
| Last 12-Month Dividend Yield | N/A | 0.91% |
| 3-Year Avg Annual Dividend | N/A | ₹50.00 |
| 3-Year Avg Dividend Yield | N/A | 0.70% |
| 3-Year Total Dividends | N/A | ₹150.00 |
| Ex-Dividend Date | N/A | Jul 25, 2025 |